Form 4: Kymera Therapeutics CEO Trades Shares Under 10b5-1 Plan

Kymera Therapeutics CEO Nello Mainolfi executed trades involving company stock and stock options under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Nello Mainolfi, CEO of Kymera Therapeutics, Inc., reported transactions on July 7, 2026, involving common stock and stock options.
• These transactions were conducted under a Rule 10b5-1 trading plan established on March 24, 2026.
• Mainolfi acquired 50,000 shares of common stock at $2.08 per share.
• Concurrently, Mainolfi disposed of 50,000 shares of common stock at $119 per share.
• The CEO also exercised stock options, acquiring 45,559 shares and 4,441 shares, respectively, with the underlying options being fully vested and exercisable.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While it involves significant stock transactions by the CEO, these were executed under a pre-defined Rule 10b5-1 plan, which is a standard compliance mechanism.

Positives

• The CEO's acquisition of 50,000 shares at a lower price ($2.08) could indicate confidence in future stock appreciation.
• The exercise of vested stock options demonstrates the CEO's continued engagement and potential benefit from the company's performance.

Negatives

• The disposal of 50,000 shares at a significantly higher price ($119) represents a substantial sale of stock by the CEO.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. The transactions are based on a pre-established trading plan.

Industry Context

StockSavvy.ai notes that the use of Rule 10b5-1 plans by executives is a common practice to diversify holdings or manage personal finances while mitigating concerns about insider trading. The significant difference between the acquisition price ($2.08) and the disposal price ($119) for the common stock reflects a substantial increase in the stock's value since the plan's inception or the options' grant.

Stakeholder Impact

• Shareholders: The sale of a significant number of shares by the CEO could be interpreted in various ways, but the execution under a 10b5-1 plan suggests it was pre-planned and not necessarily a reflection of negative sentiment towards the company's future prospects.

Key Dates

Keywords

Kymera Therapeutics, KYMR, Form 4, Insider Trading, Rule 10b5-1, Stock Options, Common Stock, CEO, Nello Mainolfi, SEC Filing